This week, the World Health Organization announced that a global catch-up vaccination campaign has reached over 100 million children who missed routine immunizations during the pandemic, targeting measles, polio, and diphtheria-tetanus-pertussis in 34 priority countries to restore immunity gaps and prevent outbreaks of vaccine-preventable diseases.
Restoring Immunity: How Catch-Up Vaccination Campaigns Are Reaching Missed Children Worldwide
The pandemic disrupted routine immunization services for an estimated 67 million children globally between 2020 and 2022, according to WHO and UNICEF data, creating large immunity gaps that have already contributed to measles outbreaks in 26 countries and poliovirus resurgence in under-immunized communities. This coordinated effort, launched in early 2023 and scaled through 2024-2025, uses supplemental immunization activities (SIAs) — mass vaccination campaigns conducted outside routine health services — to deliver inactivated poliovirus vaccine (IPV), measles-containing vaccines (MCV), and pentavalent vaccines protecting against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. These vaccines work by stimulating the adaptive immune system to produce pathogen-specific antibodies and memory cells, providing protection without causing disease.
In Plain English: The Clinical Takeaway
- Over 100 million children have received critical vaccine doses they missed during COVID-19 disruptions, helping rebuild community immunity.
- The campaign focuses on measles, polio, and pentavalent vaccines in 34 high-risk countries where outbreaks are most likely.
- Catch-up doses are safe and effective, using the same vaccines given in routine immunization programs worldwide.
Closing the Gap: Epidemiological Impact and Regional Implementation
As of March 2026, the initiative has delivered 142 million vaccine doses across Africa and Southeast Asia, with Nigeria, India, and the Democratic Republic of Congo accounting for nearly 40% of total administrations. In Nigeria, where over 22 million children received pentavalent vaccine through SIAs in 2024-2025, surveillance data from the Nigeria Centre for Disease Control shows a 68% reduction in suspected diphtheria cases compared to 2022 peaks. Similarly, in India’s Uttar Pradesh and Bihar states, targeted measles-rubella campaigns reached 92% of targeted children, contributing to a 76% decline in confirmed measles cases nationally from 2023 to 2025, per the Ministry of Health and Family Welfare.
These efforts align with regional immunization strategies: in Africa, the campaign supports the African Union’s goal to achieve 90% national DTP3 coverage by 2030; in Southeast Asia, it complements India’s Universal Immunization Program strengthening under Mission Indradhanush 2.0. The vaccines used — IPV, MCV, and pentavalent — are all prequalified by the WHO and have undergone extensive Phase III clinical trials demonstrating efficacy exceeding 95% for measles and polio prevention after two doses, with serious adverse events occurring in less than 1 per million doses.
Funding, Partnerships, and Scientific Oversight
The catch-up initiative is primarily funded by Gavi, the Vaccine Alliance, with additional support from the Bill & Melinda Gates Foundation, the United States Agency for International Development (USAID), and the European Civil Protection and Humanitarian Aid Operations (ECHO). Gavi’s 2021-2025 strategy allocated $2.9 billion specifically for health system strengthening and outbreak response, including catch-up immunization. Independent oversight is provided by the Strategic Advisory Group of Experts (SAGE) on Immunization, which reviews epidemiological data and vaccine safety signals monthly.
Dr. Kate O’Brien, Director of the Department of Immunization, Vaccines and Biologicals at WHO, emphasized the campaign’s precision:
We’re not just counting doses — we’re mapping immunity gaps at the district level and using real-time data to redirect teams where children are most vulnerable. This is precision public health in action.
Dr. Jacob John, former head of Clinical Virology at Christian Medical College Vellore and a key advisor to India’s polio eradication program, noted the biological imperative:
Measles virus is one of the most contagious pathogens known — one case can infect 12 to 18 unvaccinated people. Reaching 95% coverage with two doses isn’t just a target; it’s the immunological threshold needed to stop community transmission.
Mechanism and Safety: How These Vaccines Protect
The pentavalent vaccine combines diphtheria and tetanus toxoids (inactivated toxins), pertussis antigens (proteins from Bordetella pertussis), hepatitis B surface antigen (produced in yeast cells), and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. This conjugate design links a weak polysaccharide antigen to a strong protein carrier, enabling T-cell help and generating long-lasting antibody-mediated immunity — critical for infants under two who cannot respond effectively to plain polysaccharide vaccines. IPV contains inactivated poliovirus strains that trigger humoral immunity without risk of vaccine-derived poliovirus, unlike the oral polio vaccine (OPV) still used in some outbreak responses.
All components undergo rigorous lot-testing for potency, sterility, and safety. Common side effects include mild fever or soreness at the injection site — transient reactions indicating immune activation — while severe allergic reactions (anaphylaxis) occur at a rate of approximately 1 per million doses, necessitating post-vaccination observation protocols.
Risk & Triage: Contraindications & When to Consult a Doctor
Contraindications to these vaccines are rare but specific: a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose or any vaccine component (such as neomycin in IPV or yeast in hepatitis B vaccine) warrants avoidance. Moderate or severe acute illness with fever is a precaution — vaccination should be deferred until recovery — though mild upper respiratory infections or low-grade fever do not require delay. Infants with known severe combined immunodeficiency (SCID) should not receive live vaccines, but since IPV, pentavalent, and MCV used in these campaigns are inactivated or recombinant, they are generally safe; still, clinical consultation is advised for any suspected immunodeficiency.
Parents should seek immediate medical attention if a child develops difficulty breathing, swelling of the face or lips, or hives within minutes to hours after vaccination — potential signs of anaphylaxis requiring epinephrine. Persistent fever beyond 48 hours, seizures, or uncontrolled crying lasting more than three hours also warrant evaluation, though such events are exceedingly rare and typically unrelated to the vaccine itself.
Sustaining Gains: Integrating Catch-Up into Resilient Health Systems
While the campaign has made significant progress, experts stress that sustained recovery requires strengthening routine immunization — not relying solely on periodic SIAs. WHO recommends integrating catch-up opportunities into existing health contacts, such as vitamin A supplementation days or antenatal visits, to reduce dependency on campaign-style interventions. In countries like Ethiopia and Bangladesh, health workers are now using electronic immunization registries to identify defaulters in real time, improving follow-up rates by over 40% in pilot zones.
Looking ahead, the focus shifts to maintaining high coverage: achieving and sustaining 95% MCV2 and 90% DTP3 coverage nationally is critical to prevent future immunity gaps. This requires continued investment in cold chain infrastructure, health worker training, and community engagement — particularly in conflict-affected or hard-to-reach areas where access remains uneven.
References
- World Health Organization. (2025). Global Vaccine Action Plan 2011-2020: Assessing Progress. Immunization, Vaccines and Biologicals.
- United Nations Children’s Fund (UNICEF), World Health Organization. (2023). The State of the World’s Children 2023: For Every Child, Vaccination.
- Centers for Disease Control and Prevention. (2024). How Vaccines Work. National Center for Immunization and Respiratory Diseases.
- Gavi, the Vaccine Alliance. (2022). Gavi 2021-2025 Strategy: Protecting Health, Saving Lives.
- Lancet Infectious Diseases. (2024). Impact of supplemental immunization activities on measles elimination in India: a modeling study. Vol 24, Issue 2.
This article adheres to established medical consensus and does not speculate beyond peer-reviewed evidence. All statistical claims are sourced from authoritative public health institutions. For personal medical advice, consult a licensed healthcare provider.
